Safety And Effectiveness Of Visulas Green Selective Laser Trabeculoplasty (Slt) In Glaucoma Patients: A Retrospective, Multicenter Clinical Investigation
Published 2023 - 41st Congress of the ESCRS
Reference: FP04.04 | Type: Free paper | DOI: 10.82333/z5yq-6v50
Authors: Florian Kretz* 1 , Karsten Klabe 2 , Stefan Koinzer 3 , Karin Pillunat 4
1Ophthalmolgy,Precise Vision Augenärzte,Rheine,Germany, 2Ophthalmology,Internationale Innovative Ophthalmochirurgie GbR,Düsseldorf,Germany, 3Ophthalmology,Augenarztpraxis am Dreiecksplatz,Kiel,Germany, 4Ophthalmology,University Hospital Carl Gustav Carus an der Technischen Universität Dresden,Dresden,Germany
Purpose
To report the safety and effectiveness of Selective Laser Trabeculoplasty (SLT) using the SLT mode of the VISULAS green laser (Carl Zeiss Meditec AG, Jena, Germany) in patients with primary open-angle glaucoma (POAG). Twelve months results are presented.
Setting
The study was conducted in four research centers across Germany: Uniklinik, Dresden; Precise Vision, Rheine; Augenarztpraxis am Dreiecksplatz, Kiel; Breyer, Kaymak & Klabe Augenchirurgie, Düsseldorf.
Methods
Retrospective extension of an initially prospective interventional multi-center 3 months clinical investigation using the VISULAS green SLT in patients with POAG, who either needed a treatment escalation or commenced treatment with an IOP ≥17mmHg at baseline, with no previous glaucoma or other ocular surgery. 100 non-overlapping laser spots were applied in a single session to 360° of the trabecular meshwork (TM), and the energy was adjusted according to the pigmentation of the TM. Glaucoma medications were not changed up to the 3 months visit. From 3 to 12 months patients were managed according to routine standard of care. Outcome measures included IOP reduction, further glaucoma intervention and adverse events from baseline to month 12.
Results
25 eyes of 25 POAG patients (mean age 65.8±8.5) were included in the extension study. 5 eyes underwent a second glaucoma intervention while 1 patient showed reduction in glaucoma medications. The remaining 19 eyes had stable glaucoma treatment with no further glaucoma intervention or change in glaucoma medication. The mean number of preoperative glaucoma medications was 2.3±1.34. Mean baseline IOP (mmHg) was 20±2.11 and reduced to 16.6±2.50and 16.2±1.83 at the 3- and 12-month follow-up, respectively. 52.6% had ≥ 20% IOP reduction at 12 months. Potentially device- or procedure-related adverse events were mild to moderate: 3 postoperative IOP spikes, while 5 patients reported eye pain and discomfort. All resolved without sequelae.
Conclusions